Abstract: A recoil device is provided for a gun having a barrel with a breech. The device includes a breech nut, a brake assembly, a pneumatic spring and a counter-recoil buffer. The breech nut has first and second adjacent sides. The brake assembly includes a brake cylinder that mounts to the breech nut on the first side. The pneumatic spring mounts to the breech nut on the second side. The counter-recoil buffer attaches to the pneumatic spring. The brake cylinder and the pneumatic spring internally push fluids for recoil absorption and return in response to firing the gun.

Abstract: A shelving system has a plurality of support posts and one or more shelf assemblies, each shelf assembly having a height adjustment mechanism. A height adjustment mechanism can include a bracket attached to a shelf portion, wherein the bracket includes a channel for receiving a support post, and a latch element pivotably attached to the bracket. The latch element pivots between a first position in which the latch element engages an aperture in the support post to support the shelf assembly on the support post, and a second position in which the latch element is out of the aperture to allow the shelf assembly to move along the support post. The latch element can include a hook with a notch positionable to receive an edge of the aperture, and a side face positionable to rest or press against the support post.

Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.

Abstract: A poultice application pad includes a generally planar poultice layer for application to a treatment area of a limb of an animal, and a backing sheet, adjacent to the poultice layer, which backing sheet supports and holds the form of the poultice layer when contacting the first side of the poultice layer to the treatment area to reduce application time and displacement of the mud/clay mixture beyond the treatment area. Also disclosed is a set of such poultice application pads stacked one on top of another within a sealable container.

Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.

Abstract: The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.

Abstract: The present disclosure relates to a bidirectional communication circuit for bidirectional communication between a first differential wired network and a second differential wired network and a related method of operating the bidirectional communication circuit. In particular, the present disclosure relates to a bidirectional communication circuit designed to prevent timing glitches and simultaneous transmission of data from the first network to the second network and from the second network to the first network.

Abstract: The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and river function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.

Abstract: The present disclosure relates to a bidirectional communication circuit for bidirectional communication between a first differential wired network and a second differential wired network and a related method of operating the bidirectional communication circuit. In particular, the present disclosure relates to a bidirectional communication circuit designed to prevent timing glitches and simultaneous transmission of data from the first network to the second network and from the second network to the first network.

Abstract: A smart pacifier that performs various functions via smart device connection and application is disclosed. In all of its iterations, there is the ability to put the parent in Bluetooth or other iteration of wireless connection with the pacifier so that each of the features of the pacifier can be accessed through a smart device application, permitting each of them to be operated while the parent is out of sight of the child, and for the pacifier to shut down remotely based on direct sensory interaction with the child.

Abstract: The present disclosure includes methods of making a brine solution that include recirculating brine solution to a salt and water hopper from a holding tank. The present disclosure also includes an apparatus for making a solution that includes at least one nozzle assembly positioned inside the lower half of a hopper. The at least one nozzle assembly includes a manifold having at least two nozzles spaced apart. Each nozzle has one or more nozzle outlets that are directed away from the bottom of the hopper (e.g., toward the top of the hopper).

Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and Pharmaceutical compositions comprising the fusion polypeptide.

Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.

Abstract: Single molecules useful in vaccine compositions, and methods of making and using the same, are described.

Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.

Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.

Abstract: The present invention is directed to isolated recombinant human ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins. The proteins of the invention can be surprisingly used to restore ADA2 activity in subjects having loss-of-function mutations in ADA2 and increase differentiation of monocytes into macrophages, e.g., M2 macrophages, e.g., M2c macrophages, stimulate CD4+ T cell proliferation, and increase endothelial cell development. More specifically, the ADA2 proteins, ADA2 biologically active fragments, and ADA2 fusion proteins of the invention can be used to treat subjects having ADA2-associated diseases or disorders, including but not limited to, polyarteritis nodosa, Sneddon Syndrome, vasculitis, ischemic stroke, hemorrhagic stroke, lacunar stroke, aneurysm in the celiac artery, skin rash, skin necrosis, livedo racemosa, hepatosplenomegaly, organ failure, retinal artery occlusion, optic nerve atrophy, diplopia, cranial nerve palsy, strabismus, and low serum IgM.

Abstract: The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ?1 point reduction or a ?2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. Also provided are methods of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ?1 point reduction or a ?2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration.

Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.